Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day one, while bevacizumab...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Reardon, David A., Desjardins, Annick, Peters, Katherine B., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Bulusu, Anuradha, Threatt, Stevie, Friedman, Allan H., Vredenburgh, James J., Friedman, Henry S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616617/
https://ncbi.nlm.nih.gov/pubmed/21986722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0722-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak